Lauren Silvernail
Directeur/Membre du Conseil chez HARROW, INC.
Profil
Lauren P.
Silvernail is currently the Director at Nicox Ophthalmics, Inc. and an Independent Director at Harrow, Inc. She is also a Member of the Licensing Executives Society.
Previously, she served as an Independent Director at Harpoon Therapeutics, Inc. and Nicox SA. She was the Vice President-Business Development at Allergan, Inc. from 1995 to 2003.
Lauren also held positions as a Group Product Manager at Bio-Rad Laboratories, Inc. and as a Principal at Varian Medical Systems, Inc. From 2003 to 2012, she was the VP, Chief Financial & Accounting Officer at ISTA Pharmaceuticals, Inc. She served as the Chief Financial & Business Officer at Revance Therapeutics, Inc. in 2013 and as the CFO & Executive VP-Corporate Development at Evolus, Inc. from 2018 to 2022.
Additionally, she was a General Partner at Glenwood Ventures in 1989.
Ms. Silvernail received her undergraduate degree from the University of California, Berkeley and her MBA from UCLA Anderson School of Management.
Postes actifs de Lauren Silvernail
| Sociétés | Poste | Début |
|---|---|---|
| HARROW, INC. | Directeur/Membre du Conseil | 29/01/2024 |
| Licensing Executives Society | Corporate Officer/Principal | - |
Nicox Ophthalmics, Inc.
 Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Directeur/Membre du Conseil | 01/01/2017 |
Anciens postes connus de Lauren Silvernail
| Sociétés | Poste | Fin |
|---|---|---|
| HARPOON THERAPEUTICS, INC. | Directeur/Membre du Conseil | 11/03/2024 |
| NICOX SA | Directeur/Membre du Conseil | 27/02/2024 |
| EVOLUS, INC. | Directeur Financier/CFO | 31/05/2022 |
| REVANCE THERAPEUTICS, INC. | Directeur Financier/CFO | 29/05/2018 |
ISTA Pharmaceuticals, Inc.
 ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Directeur Financier/CFO | 01/01/2012 |
Formation de Lauren Silvernail
| University of California, Berkeley | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| BIO-RAD LABORATORIES, INC. | Health Technology |
| REVANCE THERAPEUTICS, INC. | Health Technology |
| EVOLUS, INC. | Health Technology |
| NICOX SA | Health Technology |
| HARROW, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Varian Medical Systems, Inc.
 Varian Medical Systems, Inc. Medical SpecialtiesHealth Technology Varian Medical Systems, Inc. engages in the manufacture of medical devices and software for treating cancer and other medical conditions. It operates through the Oncology Systems and Proton Solutions segments. The Oncology Systems segment designs, manufactures, sells, and services hardware and software products for treating cancer with conventional radiation therapy, and advanced treatments. The Proton Solutions segment delivers proton therapy, a form of external beam radiotherapy using proton beams for the treatment of cancer. The company was founded by William Hansen, Edward Ginzton, Russell Varian, and Sigurd Varian in 1948 and is headquartered in Palo Alto, CA. | Health Technology |
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Health Technology |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Health Technology |
| Licensing Executives Society | |
Glenwood Ventures
 Glenwood Ventures Investment ManagersFinance Glenwood Ventures is a commercial real estate investment firm that specializes in acquiring and developing various types of real estate assets, including industrial, office, life science, residential, and mixed-use properties. Glenwood Ventures was founded in 1900 and is based in Menlo Park, CA. The private company's team members have extensive experience in maximizing real estate value by identifying opportunities and operating assets for their clients and partners. | Finance |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
